---
title: Optimal [<sup>18</sup>F]FDG PET/CT Cutoff for Pathologic Complete Response
  in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab
  and Pertuzumab in the PHERGain Trial
date: '2024-04-04'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38575192/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240405180803&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: The PHERGain trial investigated the potential of metabolic imaging to
  identify candidates for chemotherapy deescalation in human epidermal growth factor
  receptor 2 (HER2)-positive, invasive, operable breast cancer with at least 1 breast
  lesion evaluable by [^(18)F]FDG PET/CT. [^(18)F]FDG PET/CT responders were defined
  as patients with an SUV(max) reduction (ΔSUV(max)) of at least 40% in all of their
  target lesions after 2 cycles of trastuzumab and pertuzumab (HP) (with or without
  ...
disable_comments: true
---
The PHERGain trial investigated the potential of metabolic imaging to identify candidates for chemotherapy deescalation in human epidermal growth factor receptor 2 (HER2)-positive, invasive, operable breast cancer with at least 1 breast lesion evaluable by [^(18)F]FDG PET/CT. [^(18)F]FDG PET/CT responders were defined as patients with an SUV(max) reduction (ΔSUV(max)) of at least 40% in all of their target lesions after 2 cycles of trastuzumab and pertuzumab (HP) (with or without ...